Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 20.69% is 39% below its 5-year average of 33.74%, near the low end of its 5-year range (14.10%–84.59%).
5.45% below its 12-month average of 21.88%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 17.85%.
NET PROFIT MARGIN
20.69%
NET PROFIT MARGIN AVG TTM
21.88%
NET PROFIT MARGIN AVG 3Y
29.27%
NET PROFIT MARGIN AVG 5Y
33.74%
NET PROFIT MARGIN AVG 10Y
32.31%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.45%
CURRENT VS 3Y AVG
-29.32%
CURRENT VS 5Y AVG
-38.68%
CURRENT VS 10Y AVG
-35.97%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
InMode Ltd.
Market Cap
$805.59M
Net Profit Margin
20.69%
TTM Avg
21.88%
3Y Avg
29.27%
5Y Avg
33.74%
Market Cap
$813.96M
Net Profit Margin
-12.35%
TTM Avg
-13.43%
3Y Avg
-52.20%
5Y Avg
-503.49%
Market Cap
$821.00M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$785.44M
Net Profit Margin
-14.52%
TTM Avg
7.87%
3Y Avg
-15.98%
5Y Avg
-254.57%
Market Cap
$785.71M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
Market Cap
$835.64M
Net Profit Margin
-5933.45%
TTM Avg
-505.88%
3Y Avg
-252.94%
5Y Avg
-252.94%
Market Cap
$837.71M
Net Profit Margin
-61.32%
TTM Avg
-78.55%
3Y Avg
-9174.62%
5Y Avg
-9174.62%
Market Cap
$770.68M
Net Profit Margin
-147.38%
TTM Avg
-372.93%
3Y Avg
-22199.44%
5Y Avg
-19748.48%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMode Ltd. (INMD) | $805.59M | 20.69% | 21.88% | 29.27% | 33.74% |
| Apnimed, Inc. (APMD)vs › | $805.62M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $813.96M | -12.35% | -13.43% | -52.20% | -503.49% |
| Jade Biosciences, Inc. (JBIO)vs › | $821.00M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | -14.52% | 7.87% | -15.98% | -254.57% |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | -7.58% | 0.29% | -4.57% | -4.54% |
| Alumis Inc. (ALMS)vs › | $835.64M | -5933.45% | -505.88% | -252.94% | -252.94% |
| Beta Bionics, Inc. (BBNX)vs › | $837.71M | -61.32% | -78.55% | -9174.62% | -9174.62% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | -147.38% | -372.93% | -22199.44% | -19748.48% |
| Geron Corporation (GERN)vs › | $769.83M | -34.17% | -136.69% | -25443.25% | -23332.75% |
Operating Margin
18.5%
Net Profit Margin
20.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 17.85% |
| 2026-03-31 | 14.10% |
| 2025-12-31 | 26.02% |
| 2025-09-30 | 23.47% |
| 2025-06-30 | 27.97% |
| 2025-03-31 | 23.37% |
| 2024-12-31 | 84.59% |
| 2024-10-31 | 39.15% |
| 2024-06-30 | 27.55% |
| 2024-03-31 | 29.52% |
| 2023-12-31 | 43.51% |
| 2023-09-30 | 37.79% |
| 2023-06-30 | 40.95% |
| 2023-03-31 | 38.19% |
| 2022-12-31 | 28.23% |
| 2022-09-30 | 40.24% |
| 2022-06-30 | 38.79% |
| 2022-03-31 | 36.05% |
| 2021-12-31 | 47.66% |
| 2021-09-30 | 47.48% |
| 2021-06-30 | 46.87% |
| 2021-03-31 | 40.66% |
| 2020-12-31 | 48.03% |
| 2020-09-30 | 40.02% |
| 2020-06-30 | 27.91% |
| 2020-03-31 | 15.91% |
| 2019-12-31 | 40.50% |
| 2019-09-30 | 40.45% |
| 2019-06-30 | 40.72% |
| 2019-03-31 | 33.14% |
| 2018-12-31 | -0.74% |
| 2018-09-30 | 33.98% |
| 2018-06-30 | 30.26% |
| 2018-03-31 | 30.44% |
| 2017-12-31 | 14.01% |
| 2017-09-30 | 18.22% |
| 2017-06-30 | 22.45% |
| 2017-03-31 | 11.81% |
